Research Analysts Offer Predictions for MRKR Q3 Earnings

Marker Therapeutics, Inc. (NASDAQ:MRKR) – Analysts at HC Wainwright lowered their Q3 2026 earnings estimates for shares of Marker Therapeutics in a research report issued to clients and investors on Tuesday, May 19th. HC Wainwright analyst P. Trucchio now anticipates that the company will earn ($0.25) per share for the quarter, down from their previous forecast of ($0.24). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Marker Therapeutics’ current full-year earnings is ($1.17) per share. HC Wainwright also issued estimates for Marker Therapeutics’ FY2026 earnings at ($0.83) EPS, Q1 2027 earnings at ($0.32) EPS, Q2 2027 earnings at ($0.35) EPS, Q3 2027 earnings at ($0.37) EPS, FY2027 earnings at ($1.34) EPS and FY2028 earnings at ($1.02) EPS.

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Marker Therapeutics in a research note on Friday, March 27th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Marker Therapeutics currently has a consensus rating of “Hold” and a consensus target price of $10.00.

Marker Therapeutics Stock Up 1.4%

MRKR stock opened at $1.41 on Thursday. The company’s 50-day simple moving average is $1.44 and its 200-day simple moving average is $1.44. Marker Therapeutics has a 52-week low of $0.81 and a 52-week high of $4.07. The firm has a market cap of $23.50 million, a P/E ratio of -2.31 and a beta of 1.43.

Marker Therapeutics (NASDAQ:MRKR) last posted its earnings results on Friday, May 15th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.18) by $0.02. Marker Therapeutics had a negative net margin of 343.03% and a negative return on equity of 73.29%. The business had revenue of $0.75 million for the quarter, compared to analyst estimates of $0.78 million.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Virtu Financial LLC purchased a new position in Marker Therapeutics in the 3rd quarter valued at about $25,000. Two Sigma Investments LP purchased a new position in Marker Therapeutics in the 3rd quarter valued at about $33,000. Jane Street Group LLC purchased a new position in Marker Therapeutics in the 2nd quarter valued at about $33,000. Boyer Financial Services Inc. purchased a new position in Marker Therapeutics in the 4th quarter valued at about $57,000. Finally, XTX Topco Ltd lifted its stake in Marker Therapeutics by 166.6% in the 4th quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock valued at $86,000 after buying an additional 36,269 shares in the last quarter. 22.39% of the stock is owned by hedge funds and other institutional investors.

Trending Headlines about Marker Therapeutics

Here are the key news stories impacting Marker Therapeutics this week:

• Positive Sentiment: Zacks upgraded Marker Therapeutics (MRKR) to a Buy rating, signaling stronger earnings optimism and a potentially supportive near-term catalyst. Article Title
• Positive Sentiment: Brookline Capital Markets raised its FY2027 and FY2030 earnings estimates for Marker Therapeutics, reinforcing a longer-term growth narrative.
• Positive Sentiment: The company’s FY2026 earnings estimate was slightly improved by Brookline Capital Markets, a small but favorable adjustment to near-term expectations.
• Neutral Sentiment: Marker Therapeutics announced the date for its 2026 annual meeting, a routine update that is unlikely to materially affect the stock on its own. Article Title
• Negative Sentiment: Brookline cut some quarterly and out-year EPS forecasts, including Q2 and Q3 2026 and FY2028/FY2029, highlighting ongoing uncertainty around the company’s path to profitability.

About Marker Therapeutics

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.